Abzu and Contera Pharma expand strategic partnership to add target identification to RNA-and siRNA therapeutic design platform
The application designs RNA therapeutics through parallel hypotheses testing of drug targets and individual antisense oligonucleotide (ASO) drug properties.
Abzu announces the U.S. Patent and Trademark Office issues patent for the technology behind the pioneering QLattice algorithm
Abzu® announced that the United States Patent and Trademark Office (USPTO) has issued Abzu Aps a patent number US 11,537,686 titled “Method of Deriving a Correlation” that protects the technology behind the pioneering QLattice® algorithm.
Abzu becomes a vetted member of the Nordic Ethical AI Landscape
Abzu® becomes a vetted member of the Nordic Ethical AI Landscape, a project that identifies, screens, and categorizes ethical Nordic AI startups and institutions.
Abzu selected partner for EU project Elegant North to create a new strategy for handling data on rare diseases
Abzu® is a selected partner for EU project Elegant North, which aims to create a new strategy for handling data on rare diseases.
Abzu reveals insights in Peptomyc’s first-ever clinically viable Myc oncogene inhibitor
The QLattice® discovery engine developed by Abzu® has accelerated scientific exploration and understanding or Peptomyc®, a biotech focused on inhibiting the cancer-causing protein Myc.
Abzu awarded multi million EIC Accelerator grant
Abzu is one of 75 selected in the highly competitive June cutoff of the 2022 EIC Accelerator program.
Abzu® is named a 2022 Gartner® “Cool Vendor”
The Abzoids are proud to share that Abzu is named a “Cool Vendor” in the 2022 Gartner Cool Vendors in AI Governance and Responsible AI — From Principles to Practice report, an annual evaluation of commercial platforms for data science and machine learning (ML), as well as for cloud AI services platforms. These platforms use […]
Abzu appoints Mette Kirstine Agger as a member of the board
Abzu, an artificial intelligence deeptech startup, is elevating its position in the life sciences with a heavy profile in biotech, Mette Kirstine Agger, appointing her as a new member of their board. For the past 12 years, Mette Kirstine Agger has been part of the management team at Lundbeckfonden and Managing Partner for Lundbeckfonden Ventures, […]
Abzu announces a new location at the Switzerland Innovation Park Basel Area – Novartis Campus
Believing in the European vision for AI This marks Abzu’s third office in Europe and the first expansion of its physical footprint since Abzu’s inception in January 2018 with joint offices in Copenhagen, Denmark and Barcelona, Spain. “Our goal is to become the leading European AI company,” says co-founder Casper Wilstrup. “Our story is that […]
Abzu and Contera Pharma partner to design RNA therapeutics for rare diseases using xAI technology
According to recent research in European Journal of Human Genetics, there are more than 6.000 rare diseases affecting more than 300 million people world-wide. Today, only 450 FDA-approved orphan drug products are available, which leaves hundreds of millions suffering from chronic diseases and at risk of early death. Nucleic acid-based medicine (NABM), also known as RNA therapeutics, is […]